DNA topoisomerases as targets for anticancer drugs

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 6, 2001, Pages 405-416

  Topcu, Z ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Anticarcinogenic drug; Multi drug resistance; Type I DNA topoisomerase; Type II DNA topoisomerase

Indexed keywords

10 BROMOACETAMIDOMETHYLCAMPTOTHECIN; 12 ETHOXYBENZO[C]PHENANTHRIDINE; 7 METHYL 10 BROMOACETAMIDOMETHYLCAMPTOTHECIN; ACRIDINE DERIVATIVE; ACTINOMYCIN DERIVATIVE; ALKALOID DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA LAPACHONE; CAMPTOTHECIN; CHLORAMPHENICOL; COUMARIN DERIVATIVE; DACTINOMYCIN; DICENTRINE; DIOSPYRIN; DISTAMYCIN A; DNA TOPOISOMERASE; ELLIPTICINE; ELLIPTICINE DERIVATIVE; EPIPODOPHYLLOTOXIN DERIVATIVE; FAGARONINE; FOSTRIECIN; GEMCITABINE; IRINOTECAN; MERBARONE; QUINOLONE DERIVATIVE; RIFAMPICIN; SURAMIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CATALYSIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMOLYSIS; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; NEPHROTOXICITY; NEUTROPENIA; REVIEW; STOMACH CANCER; TESTIS CANCER; THROMBOCYTOPENIA; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CATALYSIS; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 0035724690     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00368.x     Document Type: Review

References (90)

1. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
2. A model for the mechanism of Human Topoisomerase I
3. Structure and mechanism of DNA topoisomerase II
4. DNA supercoiling
5. 1-Naphtyridine derivatives. A new class of chemotherapeutic agents
6. Plant anti-tumor agents I: The isolation and structure of camptothecin, a novel alkaloidal leukemia and antitumor inhibitor from Camptotheca acuminata
7. Protein-associated DNA breaks in cells treated with adriamycin or ellipticin
8. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks
9. Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidine
10. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition
11. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II
12. Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts
13. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin
14. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
15. Effect of genistein on topoisomerase activity and on the growth of [Al 12] Ha-ras-transformed NIH 3T3 cells
16. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of drugs is DNA
17. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase
18. Inhibition of type II topoisomerase by fostriecin
19. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies
20. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer
21. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
22. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
23. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-lung cancer
24. In vitro antitumor effect of topoisomerase-I inhibitor. CPT-11, on freshly isolated human gastric and colorectal cancer
25. Phase I study of topotecan administered as a 21-day continuos infusion in children with recurrent solid tumors: A report from the Children's Cancer Group
26. Topoisomerase I poisons and supressors as anticancer drugs
27. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
28. Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon
29. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine; relation to DNA binding
30. Distamycin inhibition of topoisomerase I-DNA interaction: A mechanistic analysis
31. Irreversible trapping of the DNA-topoisomerase I covalent complex; affinity labelling of the camptothecin binding site
32. Induction of apoptosis in MCF-7: WS8 breast cancer cells by beta-lapachone
33. Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells
34. The S-phase cytotoxicity of camptothecin
35. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes
36. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes
37. Topoisomerase I is preferentially associated with isolated replicating simian virus 40 molecules after treatment of infected cells with camptothecin
38. Topoisomerase II inhibition in mitosis produces numerical and structural chromosomal aberrations in human fibroblasts
39. Effects of the DNA intercalators 4′-(9-Acridinylamino)-methanesulfonm-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage
40. Therapy of acute myelogenous leukemia
41. Novobiocin affinity purification of mitochondrial type II topoisomerase from the trypanosomatid Crithida fasciculata
42. Clinical development of topoisomerase-interactive drugs
43. Free radicals and anticancer drug resistance: Oxygen free radicals in the mechanism of drug cytotoxicity and resistance by certain tumors
44. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrich tumor cells by anticancer quinones
45. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
46. Oxidative destruction of DNA by the adriamycin-iron complex
47. How can iron salts mediate the degradation of nucleos(t)ides by elliptinium acetate via free-radicals
48. Phase II study of α-hydroxy-2N-methylellipticinium acetate
49. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine
50. Topology effect for DNA structure of cisplantin: Topological transformation of cisplantin-closed circular DNA adducts by DNA topoisomerase I
51. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
52. Aza-toxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine
53. Soybean isoflavones, genistein and genistin, inhibit rat myoblast proliferation, fusion and myotube protein synthesis
54. Mechanism of action of topoisomerase II-targeted antineoplastic drugs
55. Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage
56. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells
57. Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes
58. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes
59. Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells
60. DNA gyrase; structure and function
61. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells
62. 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action
63. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity
64. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines
65. Synergy and antagonism of combinations with quinolones
66. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
67. Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum
68. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum
69. Rapid development of cipro-floxacin resistance in methhicillin-susceptable and -resistant Staphylococcus aureus
70. GyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase
71. Mechanisms of multidrug resistance in cancer treatment
72. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line
73. P170 (Pgp) expression in leukemic cells after therapeutic exposure to arabinosyl cytosine
74. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge
75. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
76. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity
77. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
78. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells
79. Expression of ras oncogene p21 in prostate cancer
80. Increased resistance to cis-diamminedichloroplatinum (II) in NIH 3T3 cells transformed by ras oncogenes
81. Oncogene overexpression and de novo drug-resistance in human prostate cancer cells
82. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents
83. p53 point mutation and survival in colorectal cancer patients
84. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
85. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl
86. Novel multidrug resistance reversal agents
87. DNA sequence selectivity of topoisomerases and topoisomerase poisons
88. Mammalian mitochondrial DNA topoisomerase I preferentially relaxes supercoils in plasmids containing specific mitochondrial DNA sequences
89. A novel genetic system to detect protein-protein interactions
90. The yeast two-hybrid system and its pharmaceutical significance